Analysts expect that Mirum Pharmaceuticals (NASDAQ:MIRM) will report earnings of ($0.81) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Mirum Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.86) and the highest is ($0.76). Mirum Pharmaceuticals reported earnings of ($2.29) per share in the same quarter last year, which would suggest a positive year over year growth rate of 64.6%. The firm is scheduled to announce its next earnings results on Wednesday, August 26th.

On average, analysts expect that Mirum Pharmaceuticals will report full-year earnings of ($3.62) per share for the current financial year, with EPS estimates ranging from ($3.73) to ($3.49). For the next fiscal year, analysts forecast that the business will report earnings of ($4.61) per share, with EPS estimates ranging from ($6.29) to ($3.74). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.04).

Several equities analysts have weighed in on the stock. ValuEngine upgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Raymond James reiterated an “outperform” rating and issued a $28.00 target price (down from $30.00) on shares of Mirum Pharmaceuticals in a report on Friday, May 8th. Robert W. Baird assumed coverage on shares of Mirum Pharmaceuticals in a report on Wednesday, June 24th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Friday, May 29th. Eight equities research analysts have rated the stock with a buy rating, Mirum Pharmaceuticals has an average rating of “Buy” and an average price target of $26.14.

NASDAQ:MIRM traded up $0.18 on Tuesday, hitting $19.46. The stock had a trading volume of 64,560 shares, compared to its average volume of 105,287. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 0.02. The stock has a market cap of $487.74 million and a price-to-earnings ratio of -2.49. The company has a fifty day moving average price of $17.99 and a two-hundred day moving average price of $17.01. Mirum Pharmaceuticals has a 1-year low of $6.51 and a 1-year high of $28.31.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sofinnova Investments Inc. purchased a new stake in Mirum Pharmaceuticals during the 1st quarter worth approximately $5,860,000. Boxer Capital LLC purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $7,773,000. BlackRock Inc. increased its stake in Mirum Pharmaceuticals by 41.7% during the 1st quarter. BlackRock Inc. now owns 256,735 shares of the company’s stock worth $3,593,000 after buying an additional 75,566 shares during the period. AXA purchased a new stake in Mirum Pharmaceuticals during the 1st quarter worth approximately $2,195,000. Finally, Alyeska Investment Group L.P. increased its stake in Mirum Pharmaceuticals by 438.1% during the 1st quarter. Alyeska Investment Group L.P. now owns 145,711 shares of the company’s stock worth $2,040,000 after buying an additional 118,631 shares during the period. 73.27% of the stock is currently owned by hedge funds and other institutional investors.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: What is a Special Dividend?

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.